For the first time, the FDA has approved a cancer treatment strategy that changes therapy because molecular resistance appeared in the blood before imaging showed the cancer progressing. Pharmacists should pay attention to what this says about where medication management is going.
Something important happened in oncology on September 4.
The FDA granted accelerated approval to Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for certain adults with hormone receptor positive, HER2 negative, locally advanced or metastatic breast cancer.
But the drug itself is only part of the story.
The treatment is used after an ESR1 resistance mutation is detected during ongoing treatment with an aromatase inhibitor plus a CDK4/6 inhibitor, using an FDA authorized test.
And here is what makes this approval different.
The FDA says this is the:
First FDA approval of a cancer therapy guided by the detection of a resistance mutation in circulating tumor DNA before imaging tests show that the disease is progressing.
That is a major shift.
For decades, the basic sequence in oncology has often looked something like this:
Treat the cancer → monitor the patient → perform imaging → identify progression → change therapy
This approval introduces a different possibility:
Treat the cancer → monitor tumor DNA in the blood → identify emerging molecular resistance → change therapy before imaging demonstrates progression
We are starting to move upstream.
And that has implications far beyond one breast cancer drug.
What actually changed?
To understand why this matters, you first need to understand ESR1 mutations.
Patients with hormone receptor positive advanced breast cancer are commonly treated with endocrine therapy. Aromatase inhibitors work by reducing estrogen production, helping deprive estrogen receptor driven tumors of a signal that promotes growth.
But cancer evolves.
Tumor cells can develop mutations that allow them to become resistant to treatment.
One of those mechanisms involves mutations in ESR1.
The FDA describes ESR1 mutations as acquired resistance mutations that can develop during treatment with an aromatase inhibitor. Fewer than 5% of patients have these mutations when HR positive metastatic breast cancer is initially diagnosed, according to the FDA, but after progression on aromatase inhibitor therapy, nearly 40% may have them.
That difference matters.
The mutation often is not simply sitting there from the beginning.
It can emerge under the selective pressure of treatment.
The tumor changes.
The treatment becomes less effective.
Historically, clinicians might discover that resistance after the consequences became visible through conventional monitoring.
The tumor grows.
A lesion appears larger.
New disease appears.
Imaging confirms progression.
Then therapy changes.
But what if you could detect that biological evolution earlier?
That is where circulating tumor DNA enters the picture.
What is ctDNA?
Tumors can release small fragments of DNA into the bloodstream.
Those fragments are called circulating tumor DNA, or ctDNA.
A blood sample can sometimes identify genetic alterations occurring within the cancer without requiring another tissue biopsy.
In this case, researchers repeatedly tested blood for emerging ESR1 mutations while patients were receiving treatment.
The pivotal SERENA-6 trial tested patients’ ctDNA every two to three months.
When an ESR1 mutation appeared, but the patient had not yet developed radiographic disease progression, eligible patients were randomized.
One group switched endocrine therapy from an aromatase inhibitor to camizestrant while continuing the same CDK4/6 inhibitor.
The other group continued the aromatase inhibitor plus CDK4/6 inhibitor.
That means the treatment decision was not triggered by a new symptom.
It was not triggered by a larger tumor on a scan.
It was triggered by a molecular signal of resistance circulating in the blood.
That is the part pharmacists should remember.
We are moving from watching disease to watching biology
Healthcare has traditionally relied heavily on what we can observe after a biological process has already produced a measurable effect.
Blood pressure rises.
A1C increases.
Kidney function declines.
Symptoms appear.
A tumor grows.
Then we intervene.
But precision medicine increasingly creates the possibility of identifying changes further upstream.
In this case:
The patient appears radiographically stable.
But the biology underneath the disease is changing.
The blood detects that change.
And the medication strategy changes in response.
That is fundamentally different.
It means medication decisions may increasingly depend not only on:
Diagnosis + symptoms + laboratory values
but also on:
Diagnosis + current drug exposure + molecular characteristics + emerging resistance mechanisms + biomarkers + longitudinal monitoring
That is a far richer medication decision environment.
And pharmacists belong in it.
The results were encouraging, but there is an important caveat
The SERENA-6 trial enrolled 3,256 patients who underwent ESR1 mutation testing. Ultimately, 315 eligible patients with an emerging ESR1 mutation and no radiographic progression were randomized.
At the interim analysis used to support the approval, median progression-free survival was:
16.0 months with camizestrant plus a CDK4/6 inhibitor
versus
9.2 months with continued aromatase inhibitor plus a CDK4/6 inhibitor.
The hazard ratio for progression or death was 0.44.
Those results are substantial.
But the FDA granted accelerated approval, and that distinction matters.
The FDA specifically says it has not yet been confirmed whether intervening when the ESR1 mutation first appears, rather than waiting until confirmed disease progression, translates into meaningful clinical benefit.
Confirmatory studies are therefore required to verify and describe the benefit of this early intervention strategy.
That is an important scientific nuance.
The question is no longer simply:
Does camizestrant delay progression compared with continuing the aromatase inhibitor after an ESR1 mutation appears?
SERENA-6 showed a clear difference in progression-free survival between those strategies.
The bigger question is:
Are patients ultimately better off because we changed treatment at the molecular signal instead of waiting until conventional progression?
That question still needs further confirmation.
And that makes this approval even more interesting.
We are watching regulators work through an entirely new clinical paradigm in real time.
The scan is no longer necessarily the first sign that treatment is failing
Think about how significant that idea is.
A scan tells us what the disease has already done.
Molecular monitoring may increasingly tell us what the disease is beginning to do.
That does not make imaging obsolete.
It does not mean every cancer should suddenly be managed through serial ctDNA testing.
It does not mean every detected mutation should automatically trigger a medication change.
But it creates an entirely different type of decision point.
Instead of asking:
Has the cancer progressed?
We may increasingly ask:
Is the biology telling us that the current treatment is beginning to lose control of the cancer?
Those are different questions.
And medication experts need to understand both.
This is what precision pharmacy is starting to look like
When pharmacists hear the words precision medicine, pharmacogenomics is often the first thing that comes to mind.
CYP2C19.
CYP2D6.
TPMT.
DPYD.
HLA variants.
Those are important.
But personalized medication decisions are becoming much broader than traditional germline pharmacogenomics.
An ESR1 mutation detected from tumor DNA is not the same thing as a conventional inherited pharmacogenomic variant.
This is molecular oncology.
The genetics of the cancer itself are changing during treatment.
But the underlying principle should feel familiar to pharmacists:
Biological information is being used to determine which medication should be used, when it should be used, and whether the current therapy is still appropriate.
Now layer in everything that may surround that decision.
Companion diagnostics.
Tumor sequencing.
ctDNA.
Targeted therapies.
Resistance mechanisms.
Drug interactions.
Organ function.
Treatment sequencing.
Combination therapy.
Adverse effects.
Monitoring.
Insurance coverage.
Patient preferences.
That is an increasingly sophisticated medication-management problem.
Exactly the kind pharmacists should be preparing to participate in.
The companion diagnostic matters too
Alongside the Etcamah approval, the FDA authorized Guardant360 CDx as a companion diagnostic to identify eligible patients with ESR1 mutations.
That is another important part of precision medicine.
The medication and the diagnostic become linked.
It is no longer simply:
Which drug treats this disease?
It becomes:
Which patient has the biological characteristic that makes this drug appropriate?
The test determines the treatment pathway.
For pharmacists working in oncology, specialty pharmacy, health systems, managed care, medication access, or precision medicine, understanding companion diagnostics will become increasingly important.
Questions can include:
Was the correct biomarker tested?
Was the appropriate assay used?
When was testing performed?
Has the tumor potentially evolved since earlier testing?
Does the result meet the treatment indication?
Does the payer require documentation of the biomarker?
How does the biomarker affect therapy sequencing?
The prescription may be one line.
The medication decision behind it can involve an entire molecular workflow.
And then comes a very traditional pharmacy problem: drug safety
The futuristic part of this story is ctDNA.
The very familiar pharmacist part is medication safety.
The FDA says Etcamah’s prescribing information includes a boxed warning regarding the risk of irregular heart rhythm when Etcamah is taken with certain other medications.
Warnings and precautions also address bradycardia and potential fetal harm.
Think about what that means.
We can use an advanced molecular diagnostic to identify the right patient at precisely the right biological moment.
But someone still needs to examine the medication list.
Someone still needs to understand the combination regimen.
Someone still needs to recognize interacting medications.
Someone still needs to assess cardiac risk.
Someone still needs to educate the patient.
Someone still needs to monitor therapy.
Precision medicine does not eliminate traditional medication expertise.
It adds another layer to it.
The pharmacist of the future may need to understand both the molecular mechanism that selected the drug and the medication interaction that determines whether it can be used safely.
That is an incredibly interesting combination of skills.
Pharmacy expertise is getting deeper, not narrower
There is sometimes a tendency to think technology makes healthcare expertise less important.
I think developments like this demonstrate the opposite.
The more personalized therapy becomes, the more variables enter the medication decision.
Consider what may eventually need to be understood for a single patient:
What cancer does the patient have?
Which molecular alterations are present?
Which alterations emerged during therapy?
What treatment has already been used?
What resistance mechanism has developed?
Which targeted therapy addresses it?
Which companion diagnostic was used?
What other medications is the patient taking?
What interactions exist?
What adverse effects need monitoring?
What laboratory tests matter?
What cardiac monitoring is required?
What happens when resistance develops again?
What therapy comes next?
That is not medication management becoming simpler.
It is medication management becoming more information-rich.
And pharmacists who become comfortable operating in that environment can be incredibly valuable.
This also creates career opportunities
Not every pharmacist needs to become an oncology specialist.
That is not the message.
But pharmacists who are interested in where healthcare is going should pay attention to the ecosystem forming around precision medicine.
There are potential roles involving:
Precision medicine and molecular oncology
Pharmacists helping interpret how molecular information affects therapy selection, sequencing, monitoring, and safety.
Clinical genomics
Working within health systems or precision medicine programs to help integrate genomic information into medication decisions.
Companion diagnostics
Supporting development, implementation, education, access, and appropriate clinical use of biomarker-driven therapies.
Oncology pharmacy
Managing increasingly complex targeted treatment regimens and helping translate molecular treatment strategies into safe patient care.
Medical affairs
Educating healthcare professionals about new mechanisms, biomarkers, clinical evidence, patient selection, and treatment sequencing.
Clinical development
Helping design and interpret trials where biomarkers determine enrollment, treatment assignment, or timing of therapy.
Managed care and market access
Evaluating therapies where coverage decisions may depend on specific genetic or molecular test results.
Clinical informatics
Building systems capable of getting complex biomarker information into workflows where clinicians and pharmacists can actually use it.
Diagnostic and biotechnology companies
Working where drugs, laboratory testing, molecular data, and clinical decision-making increasingly intersect.
Again, none of this means every role requires a PharmD.
But understanding medications and understanding the biological information driving medication selection is a powerful combination.
There is another skill pharmacists will increasingly need: understanding timing
Precision medicine is not only about choosing the right drug.
Increasingly, it may be about choosing the right drug at the right biological moment.
That is what makes this approval especially interesting.
Camizestrant was not simply matched to an ESR1 mutation.
The treatment strategy was built around detecting the mutation before conventional progression appeared.
Timing became part of precision medicine.
That adds another dimension:
Right patient
Right medication
Right biomarker
Right sequence
Right time
The medication itself is only one part of the system.
Your Pharmacy Unlocked challenge this week
Give yourself five minutes.
Learn two terms:
ctDNA
and
ESR1 mutation
You do not need to become a molecular oncologist.
You do not need to memorize the SERENA-6 protocol.
You do not need to start studying every breast cancer biomarker.
Just understand the concepts.
ctDNA
Small fragments of tumor-derived DNA circulating in the bloodstream.
It can sometimes provide molecular information about a cancer through a blood sample and, in certain settings, allow detection of tumor changes before conventional methods show progression.
ESR1 mutation
An acquired mutation involving the estrogen receptor pathway that can emerge during endocrine therapy and contribute to resistance to aromatase inhibitors in HR positive advanced breast cancer.
Then ask yourself one bigger question:
What happens to pharmacy practice when medications increasingly respond to biological changes we can detect before symptoms or conventional monitoring reveal them?
Because that is the trend worth watching.
We may be entering an era of earlier medication intervention
Healthcare has spent enormous effort getting better at treating disease once we identify that something has gone wrong.
The next frontier is different.
Can we identify the biological signal that tells us something is about to go wrong?
Can we act before the conventional endpoint appears?
Can we change therapy before resistance manifests as visible progression?
Can we personalize the intervention based on what is happening inside the disease right now?
Etcamah’s accelerated approval does not answer all of those questions.
The FDA itself is making clear that additional evidence is needed to confirm whether this earlier intervention strategy ultimately delivers meaningful clinical benefit beyond the progression-free survival endpoint that supported accelerated approval.
That scientific uncertainty should not be minimized.
But neither should the importance of what just happened.
For the first time, the FDA has approved a cancer treatment strategy in which detection of a resistance mutation in circulating tumor DNA can trigger a therapy change before imaging shows progression.
That means the treatment decision has moved upstream.
From the scan.
To the blood.
From visible progression.
To molecular resistance.
And as medication decisions become more precise, more dynamic, and more dependent on complex biological information, pharmacists have an opportunity to become even more valuable.
Not simply as experts on what a drug does.
But as experts helping determine:
Which drug.
For which patient.
Based on which biomarker.
At which point in the disease.
In combination with which medications.
With which safety considerations.
That is a very different version of pharmacy.
And we just got a glimpse of it.
Resources & Citations
1. U.S. Food and Drug Administration. “FDA Grants Accelerated Approval to a New Breast Cancer Treatment.” September 4, 2026.
Primary source for the U.S. accelerated approval of Etcamah (camizestrant) with a CDK4/6 inhibitor, the approved patient population, ESR1 mutation requirement, Guardant360 CDx companion diagnostic authorization, 16.0 versus 9.2 month estimated median progression-free survival, accelerated approval requirements, boxed warning information, and FDA’s statement that this represents the first cancer therapy approval guided by detection of a ctDNA resistance mutation before imaging shows progression.
FDA approval announcement
2. Bidard FC, et al. “First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.” New England Journal of Medicine. 2025;393(6):569-580. DOI: 10.1056/NEJMoa2502929.
Peer-reviewed publication of the SERENA-6 Phase III trial. The trial prospectively tested ctDNA every two to three months for emerging ESR1 mutations, randomized patients without radiographic progression after mutation detection, and reported median progression-free survival of 16.0 months with camizestrant plus continued CDK4/6 inhibition versus 9.2 months with continued aromatase inhibitor plus CDK4/6 inhibition.
PubMed record
New England Journal of Medicine article
3. AstraZeneca. “Camizestrant combination delayed time to first progression by 55% and to second progression by 37% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 trial.” June 2, 2026.
Sponsor-reported extended follow-up from SERENA-6 showing sustained progression-free survival benefit, second progression-free survival results, and exploratory ctDNA dynamics. Updated follow-up reported median PFS of 16.8 months versus 9.2 months and substantially greater ctDNA reduction among patients switched to camizestrant.
AstraZeneca SERENA-6 updated results
4. Bidard FC, et al. “Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.” 2026.
Peer-reviewed extended SERENA-6 analysis reporting ctDNA surveillance, updated progression-free survival, second progression-free survival, and longer follow-up of the biomarker-guided early-switch strategy.
PubMed record
5. U.S. Food and Drug Administration. Oncologic Drugs Advisory Committee, Camizestrant NDA 220359, April 30, 2026.
FDA briefing materials describing the SERENA-6 design, ctDNA testing strategy, safety considerations, and the regulatory uncertainty surrounding whether switching therapy at ESR1 mutation detection before radiographic progression produces clinical benefit compared with switching therapy after conventional progression.
FDA advisory committee meeting page
6. American Society of Clinical Oncology. “Camizestrant + CDK4/6 inhibitor for the treatment of emergent ESR1 mutations during first-line endocrine-based therapy and ahead of disease progression in patients with HR+/HER2− advanced breast cancer: Phase 3 ctDNA-guided SERENA-6 trial.”
Provides trial methodology including ctDNA testing every two to three months, patient selection prior to disease progression, randomization strategy, and primary progression-free survival findings.
ASCO SERENA-6 abstract